{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:08:58Z","timestamp":1793164138246,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40265-026-02363-5","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:29:10Z","timestamp":1784608150000},"page":"1735-1745","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Orforglipron: First Approval"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7191-7391","authenticated-orcid":false,"given":"Matt","family":"Shirley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"issue":"Suppl 1","key":"2363_CR1","doi-asserted-by":"publisher","first-page":"S166","DOI":"10.2337\/dc26-S008","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes. 8. Obesity and weight management for the prevention and treatment of diabetes: standards of care in diabetes\u20132026. Diabetes Care. 2026;49(Suppl 1):S166\u201382.","journal-title":"Diabetes Care"},{"issue":"10531","key":"2363_CR2","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(25)02105-1","volume":"407","author":"MA Nauck","year":"2026","unstructured":"Nauck MA, Tuttle KR, Tsch\u00f6p MH, et al. Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. Lancet. 2026;407(10531):892\u2013908.","journal-title":"Lancet"},{"key":"2363_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s40005-025-00762-6","author":"D-H Kim","year":"2025","unstructured":"Kim D-H, Kim J-E. Recent advances and trends in oral absorption enhancements of GLP-1 receptor agonist formulations. J Pharm Investig. 2025. https:\/\/doi.org\/10.1007\/s40005-025-00762-6.","journal-title":"J Pharm Investig"},{"issue":"1","key":"2363_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2337\/ds20-0016","volume":"34","author":"DM Isaacs","year":"2021","unstructured":"Isaacs DM, Kruger DF, Spollett GR. Optimizing therapeutic outcomes with oral semaglutide: a patient-centered approach. Diabetes Spectr. 2021;34(1):7\u201319.","journal-title":"Diabetes Spectr"},{"key":"2363_CR5","unstructured":"US FDA. WEGOVY (semaglutide): US prescribing information. 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/215256s031lbl218316s003lbl.pdf. Accessed 10 June 2026."},{"key":"2363_CR6","unstructured":"US FDA. FOUNDAYO (orforglipron tablet): US prescribing information. 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/220934Orig1s000lbl.pdf. Accessed 10 June 2026."},{"issue":"778","key":"2363_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.adp5765","volume":"16","author":"KW Sloop","year":"2024","unstructured":"Sloop KW, Cox AL, Wainscott DB, et al. The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron. Sci Transl Med. 2024;16(778):1\u201316.","journal-title":"Sci Transl Med"},{"key":"2363_CR8","unstructured":"US FDA. FDA approves first new molecular entity under National Priority Voucher program [media release]. 01 Apr 2026. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program?utm_medium=email&utm_source=govdelivery."},{"key":"2363_CR9","unstructured":"Chugai Pharmaceutical. Chugai and Lilly enter into a license agreement for oral GLP-1 agonist, OWL833 [media release]. 27 Sep 2018. https:\/\/www.chugai-pharm.co.jp\/news\/cont_file_dl.php?f=180927eOWL833_License.pdf&src=[%0],[%1]&rep=130,551."},{"key":"2363_CR10","unstructured":"Google Patents. WO2023220109A1. 2023. https:\/\/patents.google.com\/patent\/WO2023220109A1\/en. Accessed 10 June 2026."},{"issue":"7","key":"2363_CR11","doi-asserted-by":"publisher","first-page":"5803","DOI":"10.1111\/dom.70783","volume":"28","author":"X Ma","year":"2026","unstructured":"Ma X, Li YG, Raha S, et al. Pharmacokinetic bioequivalence of orforglipron tablets and capsules in healthy participants with obesity or overweight. Diabetes Obes Metab. 2026;28(7):5803\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"47","key":"2363_CR12","doi-asserted-by":"publisher","first-page":"29959","DOI":"10.1073\/pnas.2014879117","volume":"117","author":"T Kawai","year":"2020","unstructured":"Kawai T, Sun B, Yoshino H, et al. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proc Natl Acad Sci USA. 2020;117(47):29959\u201367.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10522","key":"2363_CR13","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1016\/S0140-6736(25)02165-8","volume":"406","author":"DB Horn","year":"2026","unstructured":"Horn DB, Ryan DH, Kis SG, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2026;406(10522):2927\u201344.","journal-title":"Lancet"},{"issue":"10534","key":"2363_CR14","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(26)00202-3","volume":"407","author":"J Rosenstock","year":"2026","unstructured":"Rosenstock J, Yabe D, Cox D, et al. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet. 2026;407(10534):1147\u201360.","journal-title":"Lancet"},{"issue":"18","key":"2363_CR15","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1056\/NEJMoa2511774","volume":"393","author":"S Wharton","year":"2025","unstructured":"Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796\u2013806.","journal-title":"N Engl J Med"},{"issue":"11","key":"2363_CR16","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1056\/NEJMoa2505669","volume":"393","author":"J Rosenstock","year":"2025","unstructured":"Rosenstock J, Hsia S, Nevarez Ruiz L, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl J Med. 2025;393(11):1065\u201376.","journal-title":"N Engl J Med"},{"key":"2363_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04386-7","author":"LJ Aronne","year":"2026","unstructured":"Aronne LJ, Horn DB, le Roux CW, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026. https:\/\/doi.org\/10.1038\/s41591-026-04386-7.","journal-title":"Nat Med"},{"key":"2363_CR18","doi-asserted-by":"crossref","unstructured":"Welch MD, Forst TA, Jia W, et al. Orforglipron vs. dapagliflozin in type 2 diabetes inadequately controlled with metformin [abstract]. Diabetes. 2026;75(Suppl 1):1254-OR.","DOI":"10.2337\/db26-1254-OR"},{"key":"2363_CR19","doi-asserted-by":"crossref","unstructured":"Giorgino F, Dsouza S, Ludwig L, et al. Efficacy and safety of orforglipron vs. placebo added to titrated insulin glargine in adults with long-standing type 2 diabetes: ACHIEVE-5 [abstract]. Diabetes. 2026;75(Suppl 1):1253-OR.","DOI":"10.2337\/db26-1253-OR"},{"issue":"1","key":"2363_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26\u201336.","journal-title":"N Engl J Med"},{"issue":"12","key":"2363_CR21","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1093\/cvr\/cvae120","volume":"120","author":"AF Lubberding","year":"2024","unstructured":"Lubberding AF, Veedfald S, Achter JS, et al. Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node. Cardiovasc Res. 2024;120(12):1427\u201341.","journal-title":"Cardiovasc Res"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02363-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02363-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02363-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:03:36Z","timestamp":1790366616000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02363-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2363"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02363-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"11 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Matt Shirley is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":1,"name":"Ethics","label":"Authorship and Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}